MiR-30a-5p promotes cholangiocarcinoma cell proliferation through targeting SOCS3

Jia Wei Zhang1, Xing Wang1, Gao Chao Li1

  • 1Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Liver Transplantation, Nanjing, Jiangsu Province, China.

Journal of Cancer
|April 15, 2020
PubMed

Insights

MicroRNA-30a-5p (miR-30a-5p) promotes cholangiocarcinoma (CCA) cell growth by targeting SOCS3. Inhibiting miR-30a-5p may offer a therapeutic strategy for CCA patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are crucial in cancer development.
  • Cholangiocarcinoma (CCA) is a significant health concern.
  • The specific role of miR-30a-5p in CCA requires elucidation.

Purpose of the Study:

  • To investigate the role and molecular mechanism of miR-30a-5p in cholangiocarcinoma (CCA).
  • To determine the clinical significance of miR-30a-5p in CCA patients.

Main Methods:

  • Expression analysis of miR-30a-5p in CCA tissues and cells.
  • In vitro functional studies involving miR-30a-5p manipulation.
  • Dual-luciferase reporter assays to confirm target interaction.
  • Correlation analysis between miR-30a-5p expression and clinical parameters.

Main Results:

  • miR-30a-5p expression is elevated in CCA tissues and cells.
  • miR-30a-5p inhibition reduces CCA cell proliferation and induces apoptosis.
  • SOCS3 is a direct target of miR-30a-5p and its inhibition rescues proliferation.
  • Upregulated miR-30a-5p correlates with larger tumor size in CCA patients.

Conclusions:

  • miR-30a-5p promotes CCA cell proliferation by targeting SOCS3.
  • miR-30a-5p represents a potential therapeutic target for cholangiocarcinoma.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K